What Anifed treats: main uses and benefits

Anifed, a brand name for the generic medicine nifedipine, is applied across domains where additional symptomatic support is needed in contexts marked by increased discomfort or tension.

The medication is commonly used across conditions presenting with acute episodes. It is used to address symptoms related to systemic imbalance associated with high blood pressure (hypertension) and for managing symptoms associated with acute or episodic changes, such as chest pain (angina). This means it is considered relevant for easing symptoms related to heightened physiological activity in scenarios involving hypertension and angina. This application supports the management of symptoms related to systemic imbalance and acute physiological changes.

In these conditions, Anifed is applied in addressing symptoms that create noticeable functional strain. It contributes to improved comfort during periods of heightened symptoms, supporting the patient during difficult episodes by easing distress. This supports general well-being during symptomatic phases. This medication is often used when symptoms intensify and supportive relief is needed, assisting with maintaining functional stability.

Quick Fact: Relevant for Easing Symptoms related to heightened physiological activity

---

Regulatory References

1. NIH MedlinePlus overview

Anifed (Nifedipine) is officially approved for use in adults under standard labeled conditions. Eligibility is strictly defined by regulatory documents, which list specific patient groups for whom the medicine is contraindicated (must not be used) or not recommended.

Use is prohibited in patients with known hypersensitivity to nifedipine or other dihydropyridines. Absolute contraindications include conditions indicating acute cardiovascular instability, such as Cardiogenic Shock, Unstable Angina Pectoris, and use within four weeks of an Acute Myocardial Infarction. The medicine is contraindicated in pregnancy and not recommended during breastfeeding. It must not be used concurrently with the strong enzyme inducer Rifampicin.

The medicine is not recommended for use in children and adolescents under 18 years, as safety and efficacy have not been established in this age group.

Specific populations require caution and close monitoring. This applies to patients with Hepatic Impairment (liver dysfunction), Severe Hypotension (very low blood pressure), and certain severe heart conditions, including Heart Failure or Severe Aortic Stenosis.

Interactions with other medicines and products

Nifedipine (Anifed) is subject to several clinically significant interactions, primarily related to its metabolism by the CYP3A4 enzyme system and through combined pharmacodynamic effects. Official regulatory documents categorize interactions based on the mechanism and resulting clinical requirement.

Pharmacokinetic Interactions (Effects on Drug Levels)

• Strong CYP3A Inducers: Concomitant use with strong enzyme inducers, such as Rifampin, is contraindicated due to the risk of a significant reduction in Nifedipine plasma concentrations and loss of effectiveness.
• CYP3A Inhibitors: Co-administration with strong CYP3A inhibitors (e.g., Ketoconazole, Itraconazole, Erythromycin, Clarithromycin, HIV protease inhibitors) can increase Nifedipine exposure, necessitating careful monitoring and potential dose reduction.
• H2-Receptor Antagonists: Cimetidine may increase Nifedipine plasma levels, requiring cautious titration.
• Grapefruit Juice: Consumption of Grapefruit juice must be avoided as it inhibits CYP3A4, significantly increasing Nifedipine levels.

Pharmacodynamic Interactions (Combined Effects)

• Beta-Blockers and Other Anti-hypertensives: Co-administration may result in an additive hypotensive effect and requires monitoring. Specific caution is required when Nifedipine is used with beta-blockers in patients undergoing high-dose Fentanyl anesthesia.
• Other Medications: Nifedipine can increase the plasma concentrations of drugs like Digoxin and Quinidine, requiring the monitoring of these co-administered medications' blood levels and potential dose adjustments.

Anifed's Mechanism of Action: How It Works

Targeting Voltage-Dependent L-Type Calcium Channels

Anifed's primary mechanism involves acting as an inhibitor of the L-type voltage-dependent calcium channels (CaV1.x) found predominantly on vascular smooth muscle cells. This binding prevents the influx of extracellular calcium ions (Ca^2+), a molecular event that initiates the subsequent contraction process.

Interrupting Excitation-Contraction Coupling

By blocking calcium influx, Anifed directly interferes with the Excitation-Contraction Coupling pathway, which governs smooth muscle tone. This mechanism halts the molecular cascade that leads to the tightening of blood vessels, resulting in the physiological effect of vasodilation (vessel widening) in the arteries.

Modulating Systemic and Coronary Circulation

The vasodilation produced by the drug's mechanism causes two physiological changes: a reduction in Systemic Vascular Resistance (SVR) and the simultaneous widening of the coronary arteries. This causes a reduction in afterload and an increase in oxygen supply to the myocardium.

How to Use Anifed

Anifed (Nifedipine) is administered exclusively via the oral route, following specific instructions concerning dosage form, frequency, and preparation. The medicine is used in two primary oral forms: an Immediate-Release (IR) capsule and an Extended-Release (ER) tablet.

The ER tablet is administered once daily, with starting doses typically ranging from 30 mg to 60 mg. The maximum dose for certain ER formulations may reach 120 mg per day. Crucially, the extended-release tablet must be swallowed whole and must not be crushed, chewed, or divided, as this ensures the proper time-controlled delivery of the medicine. In contrast, the IR capsule is typically dosed multiple times a day, often starting at 10 mg three times a day.

Treatment is generally intended for long-term use. Dosage adjustments, or titration, are typically performed gradually over intervals of seven to fourteen days until the appropriate maintenance range is established. When discontinuing therapy, the dose must be gradually decreased.

Regarding specific administration conditions, the medicine can be taken with or without food, but consistency in daily timing is emphasized for the ER tablet. An essential rule for all patients is the avoidance of grapefruit juice. For specific patient groups, dose adjustments are sometimes required: while patients with renal impairment typically require no dose modification, those with severe hepatic impairment need careful monitoring, and a dose reduction may be necessary.

Research Evidence / Overview of Studies for Anifed (Nifedipine)

---

Evidence for Use in Systemic Hypertension

The research examining Anifed's use for systemic hypertension includes a substantial number of Randomized Controlled Trials (RCTs), comprehensive Systematic Reviews, and studies that monitored patients over defined long-term periods. Research primarily examined the change in systolic and diastolic blood pressure over defined time intervals, alongside tracking major long-term outcomes such as serious cardiovascular events and all-cause mortality. The studies mainly focused on adults with essential hypertension, with some research exploring specific subgroups, such as those with certain comorbidities like kidney dysfunction.

Studies report measurements of change in blood pressure in the observed populations receiving Nifedipine, particularly the extended-release forms. Research describes changes measured during the study period, including the rate at which target blood pressure goals were achieved by different groups of patients. Long-term observational reports describe patterns related to the incidence of cardiovascular events monitored over several years of follow-up.

Evidence for Use in Chronic Stable Angina

Anifed was evaluated in a number of RCTs and Systematic Reviews for its use in managing chronic stable chest pain. These studies monitored outcomes related to physical discomfort, primarily focusing on the frequency of angina attacks and patient-reported experiences. Research also examined changes in functional activity level, such as the ability of patients to tolerate exercise before the onset of discomfort, and monitored the use of rescue medication. The evidence contributes to the broader evidence landscape by exploring short-term changes in conditions characterized by fluctuating or episodic manifestations.

The Current Research Landscape and Uncertainties

Long-term effects are not fully established regarding all study axes, and specific comparative evidence showing durability against every alternative treatment remains lacking. While the evidence base is generally substantial for systemic hypertension, the evidence quality varies across studies, particularly for less common conditions like vasospastic angina, where reliance on smaller trials is greater. Data for certain groups, such as children or women who are pregnant or breastfeeding, remain insufficient for evidence-based conclusions. Research provides context but highlights what is known and what is still uncertain; it does not offer individual predictions.

Key Studies & References

1. Nifedipine: MedlinePlus Drug Information
2. NICE Clinical Guideline 34: Management of stable angina

Common questions about Anifed (FAQ)

Q: What is the main reason Anifed is prescribed?

A: According to the official product information, Anifed is primarily indicated for the management of two conditions: high blood pressure (hypertension) and chronic stable angina or vasospastic angina (a type of chest pain). Its use in these conditions is defined by regulatory bodies.

Q: Is Anifed a type of antibiotic?

A: No, Anifed is not an antibiotic. It belongs to a class of medicines known as calcium channel blockers.

Q: How quickly do the effects of Anifed typically start?

A: Official information indicates that the medication begins to work on the first day it is taken. However, achieving the expected clinical effects may take a period of up to two weeks for the full effects to be established.

Q: What is the average duration of action for Anifed?

A: The extended-release (ER) tablets are designed as a controlled-delivery system, formulated to deliver the medicine at an approximately constant rate over a 24-hour period, supporting the requirement for once-a-day administration.

Q: Can Anifed be taken by older adults?

A: Yes, but official documents advise that elderly patients may be more sensitive to the medicine's effects. The labeling indicates that use in older adults may require careful monitoring and potentially a lower starting dose.

Q: Is Anifed safe to use if I have kidney issues?

A: Official prescribing information describes that dose adjustments are typically not required solely for renal impairment, as the medicine's pharmacokinetics are generally not significantly influenced by the degree of kidney issues.

Q: Can Anifed affect sleep patterns?

A: Official safety information lists common side effects that include symptoms like dizziness or mood changes. While these effects could potentially interfere with sleep, insomnia itself is not typically listed as a common adverse reaction in the regulatory documents.

Q: Why are there different strengths or formulations of Anifed?

A: Different strengths and formulations, such as Immediate-Release and Extended-Release, are produced for a specific reason. This variety allows for flexible dose titration (adjustment) and provides different drug delivery profiles necessary for effective treatment, such as the once-daily dosing achieved by the extended-release system.

Q: What happens if I miss a scheduled time for Anifed?

A: Official guidelines describe a protocol for managing a missed dose. This protocol generally advises taking the missed dose as soon as remembered unless it is nearly time for the next scheduled dose, in which case the user should skip the missed dose and resume the normal schedule.

Q: How long has Anifed been available on the market?

A: The medicine nifedipine has been available for many years. For instance, the extended-release formulation was initially approved by the U.S. Food and Drug Administration (FDA) in September 1989.

Q: What should be done if an interaction with another medicine is suspected?

A: Official drug labeling emphasizes the importance of informing the prescribing healthcare team about all co-administered medications. It highlights that regular check-ups are a key part of monitoring the effects of combined therapies.

Q: Can Anifed be used long-term?

A: For chronic conditions like high blood pressure and angina, regulatory information describes the use of nifedipine as a long-term therapy, intended to help manage the condition.

Q: Does Anifed cause weight changes?

A: Safety information notes that the development of peripheral edema (swelling of the ankles or feet) is a common adverse reaction. This fluid retention is noted in the safety information as potentially being associated with unusual weight gain.

Q: Are there studies that compare Anifed to no treatment?

A: Official research summaries confirm that studies on nifedipine include Randomized Controlled Trials (RCTs). These trial designs assess the medicine's effects by comparing treated patient groups against control groups, which typically receive either an inactive substance (placebo) or standard medical care.

Q: Does Anifed interact with herbal supplements?

A: Official information advises caution with certain herbal products. Specifically, St. John's Wort is known to potentially reduce the medicine's effectiveness. Other supplements, such as Ginkgo biloba and ginseng, are also sometimes mentioned as having potential interactions.

Q: What should be done with unused Anifed?

A: Official guidelines recommend disposing of unused medication primarily through a drug take-back program or mail-back envelope. If those methods are not available, guidance provides steps for disposal with household trash by mixing the medicine with an unpalatable material and securing it in a sealed container.

Q: How is the dose of Anifed typically decided?

A: Dosage is typically determined through a process called titration. This is where the dose is started low and may be gradually increased over specific intervals, often of seven to fourteen days, until the appropriate clinical response is achieved.

Q: What are the official sources for information about Anifed?

A: Authoritative sources for information about the medicine include documentation from government regulatory bodies. These include the U.S. Food and Drug Administration (FDA), the National Institutes of Health's DailyMed and MedlinePlus, and similar agencies globally.

Q: Is Anifed used for managing pain?

A: The medicine is officially indicated for managing types of chest pain known as chronic stable angina and vasospastic angina. Additionally, some specific topical or compound formulations are authorized for conditions involving localized pain, such as anal fissures.

Q: Does Anifed affect blood pressure?

A: Yes. Anifed is indicated for the treatment of high blood pressure (hypertension). Its mechanism of action works to relax blood vessels, leading to a reduction in peripheral vascular resistance, which in turn lowers blood pressure.

Q: What is the main purpose of the research studies on Anifed?

A: Research studies focus on measuring the medicine's effect on clinically relevant outcomes. The main purpose is to determine the medicine's ability to achieve specific endpoints, such as the reduction in blood pressure in patients with hypertension and the decrease in the frequency and severity of angina (chest pain).

Q: Do children ever use Anifed?

A: Official regulatory documents state that the safety and efficacy of the medicine have not been established in the general pediatric population (children and adolescents). Appropriate studies on its use in this age group have not been performed.

Q: Can people with liver disease use Anifed?

A: Official warnings state that people with severe liver impairment are a group that requires careful monitoring when using the medicine. This is because the medicine's effects may be increased due to the body's slower process of removing it.

Q: Does Anifed cause changes in mood or anxiety levels?

A: Official safety information includes mood changes among the listed adverse reactions for the medicine.

Q: Is Anifed a type of steroid?

A: No. The medicine is classified chemically as a calcium channel blocker and is not a steroid compound.

Q: Are there specific tests a doctor might perform before prescribing Anifed?

A: The official documentation emphasizes the importance of patients undergoing regular checks and blood pressure monitoring while using the medicine.

Q: What are the statistics regarding the effectiveness of Anifed?

A: Information on effectiveness is reported in clinical study summaries that are filed with regulatory bodies. These summaries include quantitative data on the medicine's ability to achieve specific endpoints, such as the average change in blood pressure and the rate of response observed at different dosages.

Q: Is Anifed suitable for use during pregnancy?

A: Official labeling classifies nifedipine as a Pregnancy Category C drug (in some formulations). The product information states that careful monitoring must be exercised, especially when used with other agents.

Q: Can Anifed be taken with milk or juice?

A: The medicine is prescribed to be swallowed with a glass of water and can be taken with or without food. Official labeling mandates the avoidance of grapefruit juice due to a known interaction, but other common juices or milk are not specifically listed as contraindications.

Q: Are there different brand names for the medicine Anifed?

A: Yes. The medicine nifedipine is sold under various brand names globally, such as Procardia XL and Adalat CC (which are extended-release formulations). These brand names refer to the same active ingredient.

Q: Are there common reasons why people stop taking Anifed?

A: Reasons for discontinuation are typically related to the development of serious or poorly tolerated adverse effects. These can include excessive hypotension, the worsening of angina, or rare but serious events like gastrointestinal obstruction.

The storage and disposal of Anifed (Nifedipine) must strictly adhere to the conditions documented in its official labeling to maintain product quality.

Official Storage Conditions

Anifed must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from light and moisture; therefore, it is required to keep it in the original, tightly closed container and store it away from excessive heat. It is a mandatory requirement that the medication must not be frozen.

Child Safety and Disposal

The medicine must be kept out of the sight and reach of children to prevent accidental ingestion. Disposal of unused or expired Anifed should be managed through official drug take-back programs. If such a program is not available, the unused product should be mixed with an undesirable substance and placed in a sealed container before discarding it in the household trash, as specified by regulatory guidance.